Correlation between in vivo pharmacokinetics, intratumoral distribution and photodynamic efficiency of liposomal mTHPC

Lassalle, Henri-Pierre; Dumas, Dominique; Gräfe, Susanna; d'Hallewin, Marie Ange; Guillemin, François; Bezdetnaya, Lina

doi:10.1016/j.jconrel.2008.11.016

Cited by 69 publications

(56 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This liposomal formulation of Foscan (Foslip ® ) belongs to the third generation photosensitizers and seems to be a valuable alternative to Foscan in PDT. Data show that liposomal formulations of temoporfin have higher efficacy and reduced damage of healthy tissue and toxicity in the absence of light compared to Foscan [48,49]. Another example of liposomal drug using in PDT is verteporfin (Visudyne ® ), a semi-synthetic porphyrin derived from protoporphyrin [50].…”

Section: Nanomedicinementioning

confidence: 99%

“…Like for Visudyne  many studies have been published on Foslip. These include studies on the putative absence of side effects [47], efficacy and reduced damage of healthy tissue compared to the non-liposomal formulation Foscan ® [48,49]. Newer studies are related to the potential use of an intratumoral injection of a liposomal formulation of Foslip in a mouse model of local recurrence of breast cancer [129] and its photothrombic activity [130].…”

Section: Liposomes As Photosensitizer Carriersmentioning

confidence: 99%

“…Various studies have been reported on Foslip  , such as on side effects [47], photodynamic efficiency, toxicity, decreased damage of healthy tissue [48,49], tumor selectivity [164] or skin delivery [165]. Not long ago, the potential use of a liposomal formulation of Foslip  was studied in a mouse model for the local recurrence of breast cancer [129].…”

Section: Current Developmentsmentioning

confidence: 99%

See 2 more Smart Citations

Nanodrug applications in photodynamic therapy

Paszko

Ehrhardt

Senge

et al. 2011

Photodiagnosis and Photodynamic Therapy

326

215

View full text Add to dashboard Cite

SummaryPhotodynamic therapy (PDT) has developed over last century and is now becoming a more widely used medical tool having gained regulatory approval for the treatment of various diseases such as cancer and macular degeneration. It is a two-step technique in which delivery of a photosensitizing drug is followed by irradiation of light. Activated photosensitizers transfer energy to molecular oxygen which results in generation of reactive oxygen species which in turn cause cells apoptosis or necrosis. Although this modality has significantly improved quality of life and survival time for many cancer patients it still offers significant potential for further improvement. In addition to the development of new PDT drugs, the use of nanosized carriers for photosensitizers is a promising approach which might improve the efficiency of photodynamic activity and which can overcome many side effects associated with classic photodynamic therapy. This review aims at highlighting the different types of nanomedical approaches currently used in PDT and outlines future trends and limitations of nanodelivery of photosensitizers. PDT -photodynamic therapy; PGA -poly(glycolic acid); PGLA -poly(D,L-lactide-coglycolide); PLA -poly(lactic acid); PS -photosensitizer; PEG -polyethylene glycol; ALA  aminolevulinic acid; m-THPC  5,10,15,20-tetra-(m-hydroxyphenyl)chlorine; m-THPP  meso-tetra(p-hydroxyphenyl); PpIX  protoporphyrin; Hp  hematoporphyrin; Pc4  silicon phthalocyanine; Ig  immunoglobulin; Tf  transferrin; TfR  transferrin receptor; VEGF  vascular endothelial growth factor; EPR  enhanced permeability and retention effect; FRET  fluorescence resonance energy transfer; MRI  magnetic resonance imaging; RES  reticuloendothelial system; ROS  reactive oxygen species; NP  nanoparticle; ND -nanodiamonds; SNP  silica nanoparticle; AMD  age-related macular degeneration; CNV  choroidal neovascularization; PTT  photothermal therapy;

show abstract

Section: Nanomedicinementioning

confidence: 99%

Section: Liposomes As Photosensitizer Carriersmentioning

confidence: 99%

Section: Current Developmentsmentioning

confidence: 99%

See 1 more Smart Citation

Nanodrug applications in photodynamic therapy

Paszko

Ehrhardt

Senge

et al. 2011

Photodiagnosis and Photodynamic Therapy

326

215

View full text Add to dashboard Cite

show abstract

“…The higher tumor ablation rate in VPDT is not likely to be due to the presence or absence of a functional immune system in the mouse model, as better performance of VPDT compared with classical PDT for some PSs has been demonstrated in both immunodeficient and immunocompetent mice. [32][33][34]46 Although the mechanisms governing the preference of a particular PS toward a specific PDT protocol require further investigation, the present study demonstrated that a fairly good therapeutic outcome could be achieved by VPDT despite the PS itself (e.g., BAM-SiPc) showing little tumor specificity. The immunogenicity of tumor cells could be strongly enhanced by the successful induction of DAMP expression during cytotoxic treatment.…”

Section: Discussionmentioning

confidence: 64%

“…For instance, hypericin and hexamethylhypericin have higher curative rates in VPDT, whereas Photofrin, tetrabromohypericin, and Foslip work better in classical PDT. [32][33][34][35] In the past decade, we have synthesized a number of novel PSs. Among them, BAM-SiPc, an unsymmetrical bisamino silicon(IV) phthalocyanine, is one of the most potent PSs.…”

Section: Introductionmentioning

confidence: 99%

Anti-tumor immunity of BAM-SiPc-mediated vascular photodynamic therapy in a BALB/c mouse model

Yeung

et al. 2015

Cell Mol Immunol

View full text Add to dashboard Cite

In recent decades, accumulating evidence from both animal and clinical studies has suggested that a sufficiently activated immune system may strongly augment various types of cancer treatment, including photodynamic therapy (PDT). Through the generation of reactive oxygen species, PDT eradicates tumors by triggering localized tumor damage and inducing anti-tumor immunity. As the major component of anti-tumor immunity, the involvement of a cell-mediated immune response in PDT has been well investigated in the past decade, whereas the role of humoral immunity has remained relatively unexplored. In the present investigation, using the photosensitizer BAM-SiPc and the CT26 tumor-bearing BALB/c mouse model, it was demonstrated that both cell-mediated and humoral adaptive immune components could be involved in PDT. With a vascular PDT (VPDT) regimen, BAM-SiPc could eradicate the tumors of ,70% of tumor-bearing mice and trigger an anti-tumor immune response that could last for more than 1 year. An elevation of Th2 cytokines was detected ex vivo after VPDT, indicating the potential involvement of a humoral response. An analysis of serum from the VPDT-cured mice also revealed elevated levels of tumor-specific antibodies. Moreover, this serum could effectively hinder tumor growth and protect the mice against further re-challenge in a T-cell-dependent manner. Taken together, these results show that the humoral components induced after BAM-SiPc-VPDT could assist the development of anti-tumor immunity. Cellular & Molecular Immunology

show abstract